

DATE: September 27, 2021(Updates in Red)

SUBJECT: COVID-19 Emergency Medical Coding Guidance

In response to the COVID-19 emergency declaration, AHCCCS is providing emergency medical coding guidance related to applicable diagnosis and procedures codes and use of modifiers. This guidance is effective immediately and is anticipated to remain in effect for the period of the emergency. For changes that are temporary in nature, further guidance will be provided to indicate when those changes are no longer in effect.

General AHCCCS COVID-19 FAQ can be found [here](https://azahcccs.gov/AHCCCS/AboutUs/covid19FAQ.html):
<https://azahcccs.gov/AHCCCS/AboutUs/covid19FAQ.html>..

COVID-19: Diagnosis and Procedure Codes

AHCCCS has added the new procedure codes and diagnosis codes to meet guidelines that are described on the [Center for Disease Control](#) and [Centers for Medicare and Medicaid Services](#) websites. All codes are currently available for use and are listed here as they are not in the current coding books.

Diagnosis Code:

- U07.1 COVID-19, virus identified
- Effective 1/1/2021 the [CDC released new ICD-10 CM](#) codes to identify conditions resulting from COVID-19.
- Z11.52 Encounter for screening for COVID-19
- Z20.822 Contact with and (suspected) exposure to COVID-19
- Z86.16 Personal history of COVID-19
- M35.81 Multisystem inflammatory syndrome (MIS)
- M35.89 Other specified systemic involvement of connective tissue
- J12.82 Pneumonia due to coronavirus disease 2019
- **U09.9 Post COVID-19 condition, unspecified**

Procedure Codes:

- U0001 SARS-CoV-2 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel (CDC Testing Laboratories)

- NDC's are not required- Change made effective to begin date of the Code
- U0002 SARS-CoV-2/2019-nCoV (COVID-19 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel
 - NDC's are not required- Change made effective to begin date of the Code
- U0003: Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R.
- U0004: 2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R
- U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code U0003 or U0004) as described by CMS-2020-01-r2 (Effective 01/01/2021) This code is for Cross over claims only and not covered for AHCCCS only members.
- 87635 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique
- C9803 Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source
- G2023 - Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), any specimen source
- G2024 - Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), from an individual in a skilled nursing facility or by a laboratory on behalf of a home health agency, any specimen source
- 86328 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (Coronavirus Disease {COVID-19})
- 86769 Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus Disease (COVID-19))
- 87426 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) Effective 06/25/2020

- 86408 Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen Effective 08/10/2020
- 86409 Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer Effective 08/10/2020
- 86413 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative
- 87636 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique.(effective 10/06/2020)
- 87637 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique.(effective 10/06/2020)
- Q0239 Injection, bamlanivimab-xxxx, 700 mg (Effective upon FDA EUA)
- M0239 intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring (Effective upon FDA EUA)
- Q0243 Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring (Effective upon EUA from FDA)
- M0243 Injection, casirivimab and imdevimab, 2400 mg (Effective upon EUA from FDA)
- 0001A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose (Effective 12/14/2020 for 12 years and older - Pfizer)
- 0002A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose (Effective 12/14/2020 for 12 years and older - Pfizer)
- 0011A Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose ((Effective 12/18/2020 for 18 years and older - Moderna)
- 0012A Immunization administration by intramuscular injection of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose ((Effective 12/18/2020 for 18 years and older - Moderna)
- 91300 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30

mcg/0.3mL dosage, diluent reconstituted, for intramuscular use (Effective 12/14/2020 for 16 years and older - Pfizer)

- 91301 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use (Effective 12/18/2020 for 18 years and older - Moderna)
- 91302 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10¹⁰ viral particles/0.5mL dosage, for intramuscular use (Effective upon FDA EUA approval – AstraZeneca)
- 0021A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10¹⁰ viral particles/0.5mL dosage; first dose (Effective upon FDA EUA approval – AstraZeneca)
- 0022A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, chimpanzee adenovirus Oxford 1 (ChAdOx1) vector, preservative free, 5x10¹⁰ viral particles/0.5mL dosage; second dose (Effective upon FDA EUA approval – AstraZeneca)
- 91303 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10¹⁰ viral particles/0.5mL dosage, for intramuscular use
- 0031A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10¹⁰ viral particles/0.5mL dosage, single dose
- 91304 Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use (Effective upon FDA EUA approval – Novavax)
- 0041A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose
- 0042A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose

- 0003A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose. (Effective upon FDA EUA approval – Third dose)
- 0013A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose
 - The vaccine and administration codes are manufacturer specific.
 - Please view the [COVID-19 Vaccine Administration Billing Guidelines](#)
 - Do not use the SL modifier on the COVID Vaccines codes
- Resources for these coding changes can be located on the following sites:
 - [AMA \(American Medical Association\)](#) COVID Guidance Resources including CPT Assistant Articles (updated link 12/02/2020)
 - AMA has issued CPT Assistance Guides
 - AMA has published Appendix Q
 - Appendix Q: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccines
 - [CMS \(Centers for Medicare and Medicaid\)](#)
 - [CMS NDC COVID Crosswalk](#)
 - [CDC \(Centers for Disease Control and Prevention\)](#)
- CPT 99072 is NOT A COVERED BENEFIT for AHCCCS members.
- U07.2 is NOT a valid diagnosis for claims for United states (See CDC.gov 3/22/2020)

COVID-19: Use of Modifiers

AHCCCS is requiring the use of specified modifiers and a condition code related to services provided as a result of, or related to, the COVID-19 emergency. In addition, AHCCCS is providing guidance regarding time-limited, coverage of telehealth services that can be provided telephonically.

1. COVID-19 Emergency Related - "CR" Modifier - Catastrophe/Disaster.
 - a. The CR modifier must be used on all applicable claims for services provided as a result of, or related to, the national emergency declaration of March 13, 2020 related to the COVID-19 outbreak.

- b. The CR modifier must be used on all billing for the all claims for both outpatient institutional and non-institutional forms listed here:
 - i. ASC X12 837P and 837I (Outpatient)
 - ii. CMS – 1500
 - iii. NUBC UB-04 (Outpatient)
 - c. For example, the CR modifier may be used in the following instances:
 - i. Member is experiencing COVID-19 symptoms, receives influenza test with positive result, so is not tested for COVID-19 and does not have an associated dx code, but would likely not have received influenza test if not for the emergency.
 - ii. Member is unable to attend treatment program due to closures and/or quarantine related to the emergency and additional respite hours are provided, which otherwise would likely not have been received if not for the emergency.
2. COVID-19 Emergency Related - “DR” Condition Code - Disaster Related.
- a. The DR condition code must be used on all applicable claims for services provided as a result of, or related to, the national emergency declaration of March 13, 2020 related to the COVID-19 outbreak.
 - b. The DR condition code must be used on all inpatient claims listed here:
 - i. ASC X12 837I (Inpatient)
 - ii. NUBC UB-04 (Inpatient)
 - c. The DR condition code is applicable to inpatient stays for which a member has received a COVID-19 diagnosis.
3. Telephonic Telehealth Services
- AHCCCS has established two telephonic code sets that are available for use:
- a. Table I, **AHCCCS Telephonic Code Set (Temporary)** provides the lists of codes available on a temporary basis to be provided telephonically starting on dates of service March 17, 2020 until the end of the COVID-19 declared emergency.
 - i. The UD modifier must be used when billing the applicable CPT or HCPCS code to designate telephonic service.
 - b. The Place of Service (POS) is the originating site (ie, where the member is located at the time of the telephonic service delivery). (Added codes/column to the AHCCCS Telehealth Code Set)
 - c. Table II, **AHCCCS Telephonic Code Set (Permanent)** are codes that have been available for use telephonically prior to the COVID-19 declared emergency and will continue to be available after the end of the emergency. There is no change to the coding standards for these codes. When providing these services telephonically, please continue to utilize POS 02 telehealth. (Added codes/column to the AHCCCS Telehealth Code Set)

Telehealth services should otherwise continue to be billed in compliance with [AMPM 320-I Telehealth](#) and the [AHCCCS Telehealth Code List with POS criteria](#). The Table 1 and Table II AHCCCS Code Sets have been added to the AHCCCS telehealth Code List.

¹Place of Service (POS) is originating site (where member is located at the time of the telephonic service delivery)

² In order for T1015 to be utilized, one or more other services from this telephonic code list must be provided